FLGT
Fulgent Genetics, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth -15.4% ·
share flow +3.0% ·
net new positions -18.2%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 250 | $5,324 | n/a | n/a |
| Q2 2026 | 61 | -5 | 10.73M | $220.18M | +4 | −10 |
| Q1 2026 | 69 | 0 | 11.71M | $186.24M | +4 | −4 |
| Q4 2025 | 69 | +1 | 14.16M | $372.03M | +1 | n/a |
| Q3 2025 | 14 | 0 | 9.19M | $207.61M | n/a | n/a |
| Q2 2025 | 11 | -2 | 7.55M | $150.07M | n/a | −2 |
| Q1 2025 | 10 | +1 | 3.99M | $67.47M | +1 | n/a |
| Q4 2024 | 9 | -1 | 3.49M | $64.46M | n/a | −1 |
| Q3 2024 | 9 | +1 | 2.57M | $55.79M | +2 | −1 |
| Q2 2024 | 8 | n/a | 1.93M | $37.93M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 2.16M | n/a | $42.99M | 0.0% | n/c | 1 | SEC ↗ ×15 |
| 2 | Millennium Management ✦ | 1.44M | -26.8% | $28.67M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 3 | The Vanguard Group ✦ (passive) | 1.17M | n/a | $23.18M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 4 | Citadel Advisors ✦ | 603.65K | +38.5% | $12.00M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 5 | Point72 Asset Management ✦ | 544.88K | +1405.8% | $10.83M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | State Street Global Advisors ✦ (passive) | 513.80K | +1.4% | $10.21M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 513.34K | +1.6% | $10.21M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 8 | D. E. Shaw & Co. ✦ | 476.49K | +8.3% | $9.47M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 9 | Two Sigma Investments ✦ | 93.72K | +76.5% | $1.86M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 10 | T. Rowe Price ✦ | 20.71K | +5.6% | $412,000 | 0.0% | ▲ Add | 5 | SEC ↗ |
| 11 | Fidelity (FMR) ✦ | 11.57K | n/a | $230,043 | 0.0% | n/c | 1 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Marshall Wace | $269,015 | was 0.0% |
| Renaissance Technologies | $175,760 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 156 holders, 16.99M shares, $249.23M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 1.67K sh · $32,885
Officer · 2.13K sh · $41,809
Officer · 939 sh · $18,691
Officer · 1.19K sh · $23,747
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
32.3% of class · View original SEC filing ↗